BioCryst Pharmaceuticals, Inc. (BCRX) Financial Statements (2023 and Earlier)
Company Profile
| Business Address |
4505 EMPEROR BOULEVARD DURHAM, NC 27703 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 508 | 300 | 136 | 104 | 114 | 55 | 52 | ||
| Cash and cash equivalents | 504 | 272 | 114 | 27 | 50 | 22 | 29 | ||
| Short-term investments | 3 | 28 | 22 | 78 | 64 | 33 | 23 | ||
| Restricted cash and investments | 3 | 2 | 2 | 2 | 3 | 2 | 2 | ||
| Receivables | 2 | 8 | 22 | 4 | 6 | 9 | 6 | ||
| Inventory, net of allowances, customer advances and progress billings | 16 | 7 | 2 | 1 | 2 | ||||
| Inventory | 16 | 7 | 2 | 1 | 2 | ||||
| Deferred costs | 0 | 0 | 0 | 0 | |||||
| Other undisclosed current assets | 37 | 6 | 4 | 2 | 1 | 1 | 5 | ||
| Total current assets: | 566 | 324 | 164 | 114 | 125 | 67 | 66 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 9 | 7 | 7 | 9 | 10 | 10 | 5 | ||
| Long-term investments and receivables | 7 | 22 | 41 | 9 | 48 | ||||
| Long-term investments | 7 | 22 | 41 | 9 | 48 | ||||
| Other noncurrent assets | 6 | 4 | 4 | 1 | 2 | 4 | 5 | ||
| Other undisclosed noncurrent assets | 0 | 0 | |||||||
| Total noncurrent assets: | 22 | 11 | 11 | 32 | 53 | 23 | 59 | ||
| TOTAL ASSETS: | 588 | 335 | 175 | 147 | 178 | 90 | 125 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 100 | 74 | 50 | 36 | 31 | 24 | 32 | ||
| Accounts payable | 28 | 19 | 14 | 8 | 6 | 4 | 9 | ||
| Accrued liabilities | 73 | 34 | 21 | 16 | 13 | 11 | 16 | ||
| Interest and dividends payable | 22 | 15 | 12 | 12 | 9 | 7 | |||
| Deferred revenue | 1 | 0 | 2 | ✕ | ✕ | ✕ | ✕ | ||
| Debt | 31 | 40 | 34 | 35 | 28 | 30 | |||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 8 | 2 | |||
| Other undisclosed current liabilities | 2 | 0 | 2 | ||||||
| Total current liabilities: | 104 | 106 | 92 | 69 | 75 | 54 | 64 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 142 | 124 | 3 | ||||||
| Long-term debt, excluding current maturities | 136 | 120 | |||||||
| Finance lease, liability | 4 | 3 | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, liability | 6 | ✕ | ✕ | ✕ | ✕ | ||||
| Liabilities, other than long-term debt | 0 | 0 | 8 | 10 | |||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 0 | 8 | 10 | ||
| Deferred rent credit | 0 | ✕ | ✕ | ✕ | |||||
| Total noncurrent liabilities: | 148 | 124 | 3 | 0 | 0 | 8 | 10 | ||
| Total liabilities: | 252 | 229 | 96 | 70 | 75 | 63 | 74 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | (107) | (19) | 38 | 49 | 84 | 2 | 48 | ||
| Common stock | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||
| Additional paid in capital | 1,098 | 1,002 | 877 | 780 | 715 | 567 | 558 | ||
| Accumulated other comprehensive income (loss) | 0 | 0 | 0 | (0) | (0) | (0) | (0) | ||
| Accumulated deficit | (1,208) | (1,023) | (841) | (732) | (632) | (566) | (511) | ||
| Total stockholders' equity: | (107) | (19) | 38 | 49 | 84 | 2 | 48 | ||
| Other undisclosed liabilities and equity | 443 | 125 | 41 | 28 | 20 | 25 | 2 | ||
| TOTAL LIABILITIES AND EQUITY: | 588 | 335 | 175 | 147 | 178 | 90 | 125 | ||
Income Statement (P&L) ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 157 | 18 | 49 | 21 | 25 | 26 | 48 | |
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 25 | 26 | 48 | |
| Cost of revenue | (7) | (2) | (4) | (1) | (2) | (1) | ||
| Cost of goods and services sold | (7) | (2) | (4) | (1) | (2) | (1) | ||
| Gross profit: | 150 | 16 | 45 | 21 | 24 | 24 | 47 | |
| Operating expenses | (328) | (191) | (145) | (115) | (81) | (73) | (86) | |
| Operating loss: | (178) | (175) | (99) | (94) | (57) | (49) | (39) | |
| Interest and debt expense | (3) | (17) | (12) | (9) | (9) | (6) | (5) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 8 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (181) | (183) | (111) | (103) | (66) | (55) | (45) | |
| Other undisclosed loss from continuing operations before income taxes | (1) | |||||||
| Loss from continuing operations before income taxes: | (182) | (183) | (111) | (103) | (66) | (55) | (45) | |
| Income tax expense | (2) | |||||||
| Net loss: | (184) | (183) | (111) | (103) | (66) | (55) | (45) | |
| Other undisclosed net income (loss) attributable to parent | 2 | 2 | 0 | (0) | 2 | |||
| Net loss available to common stockholders, diluted: | (184) | (183) | (109) | (101) | (66) | (55) | (43) | |
Comprehensive Income ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (184) | (183) | (111) | (103) | (66) | (55) | (45) | |
| Other comprehensive income (loss) | 0 | (0) | 0 | (0) | (0) | 0 | (0) | |
| Comprehensive loss: | (184) | (183) | (111) | (103) | (66) | (55) | (45) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 2 | 2 | 0 | (0) | 2 | |||
| Comprehensive loss, net of tax, attributable to parent: | (184) | (183) | (109) | (101) | (66) | (55) | (43) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.